IRIS
D'AMICO, EMANUELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.653
NA - Nord America 1.593
AS - Asia 954
SA - Sud America 68
OC - Oceania 11
AF - Africa 6
Continente sconosciuto - Info sul continente non disponibili 3
Totale 5.288
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.576
IE - Irlanda 1.241
SE - Svezia 388
HK - Hong Kong 386
RU - Federazione Russa 376
IT - Italia 356
SG - Singapore 356
CN - Cina 114
FI - Finlandia 83
DE - Germania 80
BR - Brasile 56
IR - Iran 39
FR - Francia 26
GB - Regno Unito 25
ES - Italia 20
NL - Olanda 16
TR - Turchia 15
CA - Canada 13
PK - Pakistan 11
AU - Australia 10
AT - Austria 9
BE - Belgio 7
IN - India 7
AR - Argentina 5
CH - Svizzera 5
BD - Bangladesh 4
RO - Romania 4
A2 - ???statistics.table.value.countryCode.A2??? 3
EG - Egitto 3
UA - Ucraina 3
VE - Venezuela 3
CI - Costa d'Avorio 2
CZ - Repubblica Ceca 2
EC - Ecuador 2
GR - Grecia 2
IQ - Iraq 2
JP - Giappone 2
LT - Lituania 2
NP - Nepal 2
OM - Oman 2
TH - Thailandia 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
AZ - Azerbaigian 1
CL - Cile 1
CR - Costa Rica 1
DK - Danimarca 1
KR - Corea 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MA - Marocco 1
MD - Moldavia 1
MX - Messico 1
MY - Malesia 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PL - Polonia 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PT - Portogallo 1
PY - Paraguay 1
SA - Arabia Saudita 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
UZ - Uzbekistan 1
Totale 5.288
Salva come PNG Salva come JPEG
Città #
Dublin 1.239
Chandler 491
Hong Kong 380
Nyköping 327
Santa Clara 162
Princeton 134
Singapore 103
Wilmington 83
Helsinki 80
Ashburn 52
Des Moines 32
Rome 31
Shiraz 26
Ann Arbor 21
Moscow 20
Serra de' Conti 20
Los Angeles 18
Milan 18
Nuremberg 17
Seattle 17
Bari 16
Frankfurt am Main 15
Assago 13
Foggia 12
Granada 12
Guangzhou 12
Munich 12
Falkenstein 11
Düsseldorf 10
London 10
Cedar Knolls 9
Karachi 8
Kocaeli 8
Naples 8
Jiaxing 7
Shanghai 7
The Dalles 7
Lauterbourg 6
New York 6
Palermo 6
St Louis 6
Tehran 6
Vienna 6
Washington 6
Borås 5
Catania 5
Medole 5
Melbourne 5
Norwalk 5
Shenzhen 5
Villamagna 5
Villongo 5
Beijing 4
Brussels 4
Long Beach 4
Madrid 4
Pimonte 4
Pune 4
San Severo 4
Tsuen Wan 4
Wuhan 4
Boston 3
Camporotondo Etneo 3
Cesano Maderno 3
Florence 3
Genoa 3
Giulianova 3
Gravina di Catania 3
Hanover 3
Lucera 3
Manfredonia 3
Nanjing 3
Ottawa 3
Paris 3
Quanzhou 3
Rui'an 3
Sarno 3
Stockholm 3
São Paulo 3
Turin 3
Turku 3
Xuzhou 3
Adelaide 2
Almería 2
Andover 2
Ankara 2
Anápolis 2
Boardman 2
Buffalo 2
Cagliari 2
Caltanissetta 2
Campinas 2
Caxias do Sul 2
Central 2
Chiang Mai 2
Clearwater 2
Concorezzo 2
Erzurum 2
Franca 2
Gavere 2
Totale 3.665
Salva come PNG Salva come JPEG
Nome #
La sindrome disesecutiva nel Mild Cognitive Impairment: aspetti clinici e possibilità riabilitative 166
Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019 90
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 76
MicroRNAs 181a and 125a are highly expressed in naïve RRMS: a pilot case-control study 72
CCSVI and MS. A population-based case-control study in Catania, Sicily 72
Approccio clinico e possibilità di trattamento nella SLA 72
IMMUNOSENESCENCE AND MULTIPLE SCLEROSIS: PROGNOSTIC AND THERAPEUTIC IMPLICATIONS 65
Morfometria delle strutture del tronco encefalico in pazienti affetti da atassia spino-cerebellare tipo 2 (SCA 2): indicatore diagnostico e riabilitativo? 64
Are oligoclonal bands associated to lower retinal layer thickness at the time of relapsing remitting multiple sclerosis diagnosis? Evidence from an exploratory study 61
Long term follow-up of combination therapy with inf-eta and cyclophosphamide relapsing-remitting MS patients 60
An update on the pharmacological management of pain in patients with multiple sclerosis 60
Effects of inpatient and outpatient rehabilitation setting on disability and quality of life of patients with multiple sclerosis: a randomized controlled study 59
Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal 59
Employment status in MS patients: a population-based study 57
Disease trajectory in secondary progressive multiple sclerosis: a ten years follow-up study 57
Neuropsychological pattern of cognitive dysfunction in clinically isolated syndrome suggestive of MS 56
Use of a low-cost, commercially available gaming console (Nintendo-WII) foe rehabilitation of patients with multiple sclerosis: results of a pilot study 56
Psychological and social findings of patients with early multiple sclerosis or clinically isolated syndrome 56
Dysphagia in Multiple Sclerosis 56
Comparison of Two Therapeutic Strategies in Active Relapsing-Remitting MS: Cyclophosphamide as Induction for 12 Months Follewed by Interferon Beta Versus Interferon Beta. A Two-Year Randomized Trial 56
Clinical Evolution of Relapsing Remitting Late Onset Multiple Sclerosis: A Nine Year Follow-Up Study 55
Cognitive dysfunction in multiple sclerosis. A population based study in Catania, Sicily 54
Negative prognostic impact of spinal demyelinating lesions at clinical onset in relapsing-remitting multiple sclerosis 54
A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives 53
Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis 53
Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications 51
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 51
Can new chemical therapies improve the management of multiple sclerosis in children? 51
Management of dysphagia in multiple sclerosis: current best practice 51
Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort 51
Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis 51
Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update 50
Cyclophosphamide induction therapy versus conventional therapy: a pilot study 50
Association between dietary intake and function in amyotrophic lateral sclerosis 49
WII may improve physical abilities in multiple sclerosis: a randomized single blind study 49
The association of CCSVI and MS is not a risk factor for cognitive impariment in MS 49
Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study 48
Validation of the DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis 48
Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD) 48
Unsatisfactory clinical and MRI response to DMTS in patients with late onset relapsing-remitting MS 47
A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis 47
Mesenchymal Stem Cell-Derived Extracellular Vesicles and Their Therapeutic Use in Central Nervous System Demyelinating Disorders 47
Multiple sclerosis patients preferences in decision making process 46
Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD) 46
Cyclophosphamide induction therapy versus conventional therapy: a pilot study 45
Gender related side effects of interferon-beta treatment in multiple sclerosis patients 45
Autoimmune liver disease and multiple sclerosis: state of the art and future perspectives 45
An update on the safety of treating relapsing-remitting multiple sclerosis 44
First-line therapies in Late Onset Multiple Sclerosis: an Italian registry study 43
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 43
Conventional brain MRI could be a predictor of post partum relapse in multiple sclerosis 42
Multidisciplinary approach of amyotrophic lateral sclerosis: a centre experience 41
Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register 39
Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab 38
Cognitive impairment in clinical isolated syndrome suggestive of multiple sclerosis: association with brain imaging and retinal nerve fiber layer thickness 38
The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019 37
Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience 37
Metabolic Abnormalities, Dietary Risk Factors and Nutritional Management in Amyotrophic Lateral Sclerosis 37
Five insights from the Global Burden of Disease Study 2019 36
Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019 36
The DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis 36
Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study 36
An Association of Framingham Risk Score with Patient Determined Disease Steps in a Cohort of Relapsing-Remitting Multiple Sclerosis Patients: An Italian Real-World Monocentric Experience 35
Switching to immunosuppressant agents in secondary progresive multiple sclerosis patients: is it really effective? 35
Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience 35
Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience 35
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 35
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register 35
Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019 35
Wegener’s Granulomatosis Presenting as An Intracranial Hypertension Syndrome Treated with High Dose of Cyclophosphamide 34
Real-life impact of early interferonβ therapy in relapsing multiple sclerosis 34
Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study 34
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study 33
Palliative care in progressive multiple sclerosis 33
Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study 32
Gender related thyroid dysfunction and autoimmunità in multiple sclerosis patients treated with interferon-beta 32
Prevalence of dysphagia in a consecutive cohort of subjects with MS using fibre-optic endoscopy 32
Treatment options of cognitive impairment in multiple sclerosis 32
Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience 32
Exploring polypharmacy phenomenon in newly diagnosed relapsing–remitting multiple sclerosis: a cohort ambispective single-centre study 32
Review: Patient-reported outcomes in multiple sclerosis care 32
Dietary Phenolic Acids and Their Major Food Sources Are Associated with Cognitive Status in Older Italian Adults 31
Toxoplasma gondii and multiple sclerosis: a population-based case–control study 31
Serum and CSF N-acetyl aspartate Levels differ in multiple sclerosis and neuromyelitis optica 31
Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS 31
Frequency and severity of headache is worsened by Interferon-β therapy in patients with multiple sclerosis 31
Monocytic myeloid derived suppressor cells in hematological malignancies 31
Disability may influence patient willingness to partecipate in decision making on first-line therapy in multiple sclerosis 30
CSF neurotoxic metals/metalloids levels in amyotrophic lateral sclerosis patients: comparison between bulbar and spinal onset 30
Negative prognostic impact of MRI spinal lesion in the early stages of relapsing-remitting multiple sclerosis 30
Genetic burden of common variants in progressive and bout-onset multiple sclerosis 30
Risk factors in multiple sclerosis: a population-based case-control study in Sicily. Background and methods 30
Pregnancy outcomes in multiple sclerosis patients previously treated with cyclophosphamide 30
Switching therapy: how and why in a real word setting cohort of persons with multiple sclerosis in Catania 30
Myeloid-derived Suppressor Cells and Multiple Sclerosis 29
Injectable versus oral first-line multiple sclerosis therapies: knows and unknowns from observational studies 29
Cognitive-motor dual-task interference:A systematic review of neural correlates 29
Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study 29
May baseline JCV status influence the MS clinical evolution during Natalizumab treatment? Evidence from a multicenter-2 years-prospective study 29
The Dysphagia in Multiple Sclerosis Questionnaire Correlates with Fiber-Optic Endoscopic Examination for Detecting Swallowing Deficits in MS 29
Totale 4.494
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.127
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.127
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202125 0 0 0 0 0 0 0 0 0 24 0 1
2021/2022893 5 0 1 0 363 30 14 47 97 93 21 222
2022/20232.663 270 115 199 121 48 210 16 182 1.373 45 52 32
2023/2024480 57 47 31 32 75 58 30 52 26 19 19 34
2024/20251.818 110 72 68 42 41 265 341 107 586 150 36 0
Totale 5.879